Landscape review and analysis of Canada’s pharmaceutical drug data and advice to support the development of a national drug data strategy

The Canadian Drug Agency Transition Office requires one (1)
Senior Level Business Consultant to provide expert analysis with
respect to developing a data strategy for the pharmaceutical
management system. The analysis will include three distinct phases
of work: Phase 1 – Review of the Drug Data Landscape, Phase 2 –
Analysis of Barriers, Strengths and Opportunities for improving
access to Drug Data and Phase 3 – Advice on getting started and the
Canadian Drug Agency’s role. The Business Consultant will be
required over a period of approximately 14 weeks.